Sentences with phrase «new earnings reports»

A further reminder of volatility in the industry came today after new earnings reports.

Markets in Europe managed to edge out some late gains and close higher Thursday as investors digested comments from ECB (European Central Bank) policymakers, new earnings reports and optimism over tax reforms in the U.S.

European stocks closed higher on Thursday as investors digested new earnings reports and responded to more comments from Fed Chair Janet Yellen.

U.S. government debt prices were lower on Monday morning as investors monitored U.S. - Russia relations and digest new earnings reports.

Markets in Europe managed to edge out some late gains and close higher Thursday as investors digested comments from ECB) policymakers and new earnings reports.

Outside of this, it looks like Capcom did not share any specific shipment or sales figures for any other titles in this newest earnings report.

Activision Blizzard at the moment introduced as a part of its newest earnings report that the hero shooter «continues so as to add new gamers,» nearly 24 months after its launch in May 2016.

Not exact matches

Netflix reported its third - quarter earnings on Wednesday, and a key metric disappointed: new subscribers.

Without further ado, Cramer presented his game plan for a busy week of earnings, including reports from Macy's, Lowe's, Foot Locker and a special hearing with the new head of the Federal Reserve.

The earnings report forApple's second fiscal quarter is less than two weeks away, and much as we like to obsesses about the new Watch, it hasn't earned Apple a penny yet.

In an interview with CNBC, Dell also said this new offering would be good for Snap — which is a large user of cloud services and reports earnings for the first time this week.

Analysts were expecting the bank to report adjusted earnings — which don't include short - term impacts of the new tax law — of $ 1.19 a share.

«Of course, as important as the non-farm payroll report is, at the end of the day, what really matters for individual stocks are the earnings, and we kick off a brand new earnings season on Tuesday,» Cramer said.

Yahoo's fourth - quarter earnings report will provide an update of new CEO Marissa Mayer's efforts to revive the Internet company's revenue growth.

In the meantime, this week brought fresh evidence of China's rising prowess as the country's two tech giants, Alibaba and Tencent, reported record quarterly earnings, prompting the New York Times to point out that the two companies now rank alongside Apple, Google, Facebook, Microsoft and Amazon as the world's most highly valued companies.

Then, when Zynga officials presented its second - quarter earnings report on July 25, in which the company lowered its outlook «to reflect delays in launching new games, a faster decline in existing Web games due in part to a more challenging environment on the Facebook Web platform, and reduced expectations for Draw Something,» the company's stock price plunged, falling some 35 percent overnight.

That means if you earned $ 100, you'd report $ 118 as dividend income and be charged 72 % on those earnings (the new Dividend Tax Credit rate for non-eligible dividends), rather than the 67 %.

Pfizer, the U.S. drug giant behind blockbuster treatments like Viagra and the pneumonia vaccine Prevnar, reported fourth quarter 2017 earnings which easily beat Wall Street analyst expectations, including a massive $ 11 billion boost from President Donald Trump's new tax cuts.

However, in February, Coca - Cola announced it wanted to move into healthier beverage categories, and according to its latest earnings report, its newer low - and no - sugar product lines have been growing.

General Electric reported third - quarter earnings that were barely half of what Wall Street expected, and its new CEO did not shy away from the miss.

Equities in Europe closed lower Wednesday afternoon as investors began to focus on earnings at the start of a new reporting season.

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

The Corning, New York - based company reported core earnings of 43 cents per share, beating the average analyst estimate of 41 cents, according to Thomson Reuters.

In its most recent earnings report, EOG Resources said that its return target for new wells is 3 0 % after tax at $ 40 oil, while Pioneer's internal rate of return expectations is for 50 % -100 % after tax with oil at $ 55.

Wells Fargo on Friday reported an earnings beat, helped by the new tax law.

According to the December jobs report, average hourly earnings grew by 2.9 %, a new post-crisis high and slightly beating the Bloomberg economists» consensus expectation of 2.8 %.

CIBC was also the first of the Canadian banks to report its earnings after the introduction of a new accounting standard known as IFRS 9 that puts more emphasis over expected losses over the life of a loan compared to previous guidelines.

Aside from earnings news, Europe was seen divided after the latest developments in Brexit talks saw France and Germany toughen their stance towards the U.K., claiming that they would expect an upfront gross payment of up to 100 billion euros ($ 109 billion), according to new reports from the Financial Times.

Japanese videogames maker Nintendo Co Ltd reported its biggest third - quarter operating profit in eight years, driven by smashing demand for its new Switch games console, and said it expected annual earnings to outstrip its previous estimate.

Ford is due to report its first - quarter earnings on Wednesday and is expected to offer some new information about cost - cutting.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The company reported earnings and revenue for the first quarter that were roughly in line with consensus estimates, but did not provide much new color on an unfavorable tax allowance decision from federal regulators.

Judging by the most shorted stocks traded on the New York Stock Exchange between the March 29 and April 13 settlement dates, sellers were reducing their stakes ahead of earnings reports.

McDonald's reported a solid set of Q1 earnings where the new dollar menu drove higher same - store sales growth.

Since its last earnings call, First Solar reports 1.5 GW of module bookings, between third - party sales and new projects.

New York - based drugmaker and Dow - 30 component Pfizer (PFE — Free Pfizer Stock Report) reported first - quarter earnings of $ 0.59 a share, versus $ 0.51 in the comparable period of 2017.

The earnings report followed weeks of tumult for Facebook, after a controversy erupted last month when The New York Times and other news outlets reported that millions of Facebook users» private information had been harvested by Cambridge Analytica, a political firm with ties to the Trump campaign.

NEW YORK (Reuters)- The S&P 500 ended lower on Thursday after a choppy session as disappointing earnings reports from several companies offset strong economic data.

The Dow component reported better than expected earnings and revenue in the most recent quarter and a big source of the company «s growth came from soft drinks, especially all those new diet Coke flavors.

New York Life reported another successful year in 2017, with record operating earnings of $ 2.06 billion and a record $ 1.8 billion dividend payout.

New Jersey - based drugmaker and Dow - 30 component Merck (MRK) reported first - quarter earnings of $ 0.27 a share, versus $ 0.56 in the comparable period of 2017.

05/02/2017 New York - based drugmaker and Dow - 30 component Pfizer (PFE) has reported first - quarter earnings of $ 0.51 a share, versus $ 0.49 in the comparable period of 2016.

New York - based drugmaker and Dow - 30 component Pfizer (PFE) reported first - quarter earnings of $ 0.59 a share, versus $ 0.51 in the comparable period of 2017.

All markets will continue to focus on the volatility in the equity and bond markets, geopolitical events, developments with the Trump Administration, corporate earnings, oil prices, and will turn to reports tomorrow on Japan's Leading Index and Machine Tool Orders, German IFO, US Case - Shiller Home Price Index, New Home Sales, Richmond Fed and Consumer Confidence for near term guidance.

08/01/2017 New York - based drugmaker and Dow - 30 component Pfizer (PFE) has reported second - quarter earnings of $ 0.51 a share, versus $ 0.33 in the comparable period of 2016.

As our clients know, New Constructs» ratings are unbiased, fully independent and reflect analysis of the entire annual report, not just [misleading] accounting earnings.

New Jersey - based drugmaker and Dow - 30 component Merck (MRK — Free Merck Stock Report) reported first - quarter earnings of $ 0.27 a share, versus $ 0.56 in the comparable period of 2017.

NEW YORK (Reuters)- When Wall Street's biggest banks report first - quarter earnings in the days ahead, investors should see a welcome resurgence in trading revenue growth thanks to the biggest jump in market volatility since President Donald Trump's election.

The new research paper follows on a report last year co-authored by Prof. Wolfson and two other researchers, who concluded many of Canada's wealthiest people are funnelling a large portion of their income through CCPCs that are not reflected in standard measures of individual earnings.

NEW YORK, April 11 When Wall Street's biggest banks report first - quarter earnings in the days ahead, investors should see a welcome resurgence in trading revenue growth thanks to the biggest jump in market volatility since President Donald Trump's election.